Technology
Health
Biotechnology
Trillium Therapeutics
$0.709876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.0479 (7.23%) Today
-$0.01 (-1.41%) After Hours
Why Robinhood?
You can buy or sell TRIL and other stocks, options, ETFs, and crypto commission-free!
About
Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Read More Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.
Employees
60
Headquarters
Mississauga, Ontario
Founded
2004
Market Cap
9.73M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
191.16K
High Today
$0.717
Low Today
$0.639
Open Price
$0.6618
Volume
885.29K
52 Week High
$8.10
52 Week Low
$0.55
Collections
Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2014 IPO
Canada
News
Simply Wall StMar 8
The Trillium Therapeutics (TSE:TRIL) Share Price Is Down 95% So Some Shareholders Are Rather Upset
Long term investing works well, but it doesn’t always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. Spare a thought for those who held Trillium Therapeutics Inc. (TSE:TRIL) for five whole years – as the share price tanked 95%. And it’s not just long term holders hurting, because the stock is down 90% in the last year. Shareholders have had an even rougher run lately, with the share price down 67% in the last 90 days. We really hope anyone holding throu...
Markets InsiderFeb 22
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
TORONTO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 6,550,000 common share units (the “Common Share Units”) of the Company and 12,200,000 Series II Non-Voting Convertible First Preferred Share units (the “Series II First Preferred Share Units”) of th...
Price Paid on Robinhood
49% Lower
Right Now
52 Week Low
$0.55
Average Price Paid
$1.37
52 Week High
$8.10
Earnings
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
Available Mar 11, After Hours